chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Blood bicarbonate normal, Blood fibrinogen increased, Blood pH increased
Clinical narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/04, Pfizer, dose #2 10/02 Pt cc: dyspnea, cough, myalgias, fatigue, cough, exposure: unknown 10/12 pt admit to medicine cc shortness of breath : dx: ACUTE HYPOXIC RESPIRATORY FAILURE DUE TO COVID-19 PENUMONIA LOS: 10 days 10/21 u/s abdomen impression: 1. New bilateral obstruction or pneumoperitoneum. 10/12 CXR impression: 1. New bilateral airspace opacities could relate to pneumonia, including viral. 10/12 CTA PE impression: 1. Technically suboptimal study. No pulmonary embolus in the large central pulmonary arteries. Limited evaluation of the segmental and subsegmental pulmonary arteries. 2. Nonspecific groundglass densities in the lungs probably represent covid 19 pneumonia. Pleas correlate clinically and follow-up as appropriate. 3. Right Pulmonary nodules measuring up to 1.9 cm as above are again noted. Further evaluation and follow-up will be helpful as clinically appropriate. 4. Mild splenomegaly. 5. Nonobstructing left renal calculus. 10/12 TROPONIN I: <0.016 10/12 PT/INR: 16.7/1.49 10/12 FERRITIN: 1035.7 10/12 CRP: 11.387 10/12 PROCALCITONIN: ,0.05 10/12 BNP: 12.0 10/12 COVID swab, result: detected 10/12 DDIMER: 0.98 10/12 SARS-COV-2 Variant Sequencing result: pending 10/12 ABG i-pH 7.47, i-PCo2 38, i-PO2 61, i-HCO3 27.3 10/13 FIBRINOGEN: 480 10/13 DDIMER: 0.83 10/13 ESR: 44 10/14 FIBRINOGEN: 406 10/14 DDIMER: 0.59 10/14 EST: 25 10/14 ABG: I-pH 7.44, i-PCo2 41, i-PO2 66, i-HCO3 27.8 10/15 FIBRINOGEN: 296 10/15 DDIMER: 0.60 10/15 ESR: 27 10/16 FIBRINOGEN: 300 10/16 DDIMER: 0.72 10/16 ESR: 18 10/17 FIBRINOGEN: 253 10/17 DDIMER: 0.92 10/17 ESR: 18 10/18 F8BR8H9GEH: 240 10/18 DDIMER: 0.93 10/18 ESR: 19 10/19 FIBRINOGEN: 242 10/19 DDIMER: 0.90 10/19 ESR: 13 10/21 FIBRINOGEN: 220 10/21 DDIMER: 0.67 10/21 ESR: 6 08/21 FIBRINOGEN: 197 08/21 DDIMER: 0.83 08/21 ESR: 4
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Brain natriuretic peptide normal, C-reactive protein increased, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal
Clinical narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/04, Pfizer, dose #2 10/02 Pt cc: dyspnea, cough, myalgias, fatigue, cough, exposure: unknown 10/12 pt admit to medicine cc shortness of breath : dx: ACUTE HYPOXIC RESPIRATORY FAILURE DUE TO COVID-19 PENUMONIA LOS: 10 days 10/21 u/s abdomen impression: 1. New bilateral obstruction or pneumoperitoneum. 10/12 CXR impression: 1. New bilateral airspace opacities could relate to pneumonia, including viral. 10/12 CTA PE impression: 1. Technically suboptimal study. No pulmonary embolus in the large central pulmonary arteries. Limited evaluation of the segmental and subsegmental pulmonary arteries. 2. Nonspecific groundglass densities in the lungs probably represent covid 19 pneumonia. Pleas correlate clinically and follow-up as appropriate. 3. Right Pulmonary nodules measuring up to 1.9 cm as above are again noted. Further evaluation and follow-up will be helpful as clinically appropriate. 4. Mild splenomegaly. 5. Nonobstructing left renal calculus. 10/12 TROPONIN I: <0.016 10/12 PT/INR: 16.7/1.49 10/12 FERRITIN: 1035.7 10/12 CRP: 11.387 10/12 PROCALCITONIN: ,0.05 10/12 BNP: 12.0 10/12 COVID swab, result: detected 10/12 DDIMER: 0.98 10/12 SARS-COV-2 Variant Sequencing result: pending 10/12 ABG i-pH 7.47, i-PCo2 38, i-PO2 61, i-HCO3 27.3 10/13 FIBRINOGEN: 480 10/13 DDIMER: 0.83 10/13 ESR: 44 10/14 FIBRINOGEN: 406 10/14 DDIMER: 0.59 10/14 EST: 25 10/14 ABG: I-pH 7.44, i-PCo2 41, i-PO2 66, i-HCO3 27.8 10/15 FIBRINOGEN: 296 10/15 DDIMER: 0.60 10/15 ESR: 27 10/16 FIBRINOGEN: 300 10/16 DDIMER: 0.72 10/16 ESR: 18 10/17 FIBRINOGEN: 253 10/17 DDIMER: 0.92 10/17 ESR: 18 10/18 F8BR8H9GEH: 240 10/18 DDIMER: 0.93 10/18 ESR: 19 10/19 FIBRINOGEN: 242 10/19 DDIMER: 0.90 10/19 ESR: 13 10/21 FIBRINOGEN: 220 10/21 DDIMER: 0.67 10/21 ESR: 6 08/21 FIBRINOGEN: 197 08/21 DDIMER: 0.83 08/21 ESR: 4
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Dyspnoea, Fatigue, Fibrin D dimer, International normalised ratio increased
Clinical narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/04, Pfizer, dose #2 10/02 Pt cc: dyspnea, cough, myalgias, fatigue, cough, exposure: unknown 10/12 pt admit to medicine cc shortness of breath : dx: ACUTE HYPOXIC RESPIRATORY FAILURE DUE TO COVID-19 PENUMONIA LOS: 10 days 10/21 u/s abdomen impression: 1. New bilateral obstruction or pneumoperitoneum. 10/12 CXR impression: 1. New bilateral airspace opacities could relate to pneumonia, including viral. 10/12 CTA PE impression: 1. Technically suboptimal study. No pulmonary embolus in the large central pulmonary arteries. Limited evaluation of the segmental and subsegmental pulmonary arteries. 2. Nonspecific groundglass densities in the lungs probably represent covid 19 pneumonia. Pleas correlate clinically and follow-up as appropriate. 3. Right Pulmonary nodules measuring up to 1.9 cm as above are again noted. Further evaluation and follow-up will be helpful as clinically appropriate. 4. Mild splenomegaly. 5. Nonobstructing left renal calculus. 10/12 TROPONIN I: <0.016 10/12 PT/INR: 16.7/1.49 10/12 FERRITIN: 1035.7 10/12 CRP: 11.387 10/12 PROCALCITONIN: ,0.05 10/12 BNP: 12.0 10/12 COVID swab, result: detected 10/12 DDIMER: 0.98 10/12 SARS-COV-2 Variant Sequencing result: pending 10/12 ABG i-pH 7.47, i-PCo2 38, i-PO2 61, i-HCO3 27.3 10/13 FIBRINOGEN: 480 10/13 DDIMER: 0.83 10/13 ESR: 44 10/14 FIBRINOGEN: 406 10/14 DDIMER: 0.59 10/14 EST: 25 10/14 ABG: I-pH 7.44, i-PCo2 41, i-PO2 66, i-HCO3 27.8 10/15 FIBRINOGEN: 296 10/15 DDIMER: 0.60 10/15 ESR: 27 10/16 FIBRINOGEN: 300 10/16 DDIMER: 0.72 10/16 ESR: 18 10/17 FIBRINOGEN: 253 10/17 DDIMER: 0.92 10/17 ESR: 18 10/18 F8BR8H9GEH: 240 10/18 DDIMER: 0.93 10/18 ESR: 19 10/19 FIBRINOGEN: 242 10/19 DDIMER: 0.90 10/19 ESR: 13 10/21 FIBRINOGEN: 220 10/21 DDIMER: 0.67 10/21 ESR: 6 08/21 FIBRINOGEN: 197 08/21 DDIMER: 0.83 08/21 ESR: 4
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Lung opacity, Myalgia, Nephrolithiasis, Obstruction, PCO2 normal
Clinical narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/04, Pfizer, dose #2 10/02 Pt cc: dyspnea, cough, myalgias, fatigue, cough, exposure: unknown 10/12 pt admit to medicine cc shortness of breath : dx: ACUTE HYPOXIC RESPIRATORY FAILURE DUE TO COVID-19 PENUMONIA LOS: 10 days 10/21 u/s abdomen impression: 1. New bilateral obstruction or pneumoperitoneum. 10/12 CXR impression: 1. New bilateral airspace opacities could relate to pneumonia, including viral. 10/12 CTA PE impression: 1. Technically suboptimal study. No pulmonary embolus in the large central pulmonary arteries. Limited evaluation of the segmental and subsegmental pulmonary arteries. 2. Nonspecific groundglass densities in the lungs probably represent covid 19 pneumonia. Pleas correlate clinically and follow-up as appropriate. 3. Right Pulmonary nodules measuring up to 1.9 cm as above are again noted. Further evaluation and follow-up will be helpful as clinically appropriate. 4. Mild splenomegaly. 5. Nonobstructing left renal calculus. 10/12 TROPONIN I: <0.016 10/12 PT/INR: 16.7/1.49 10/12 FERRITIN: 1035.7 10/12 CRP: 11.387 10/12 PROCALCITONIN: ,0.05 10/12 BNP: 12.0 10/12 COVID swab, result: detected 10/12 DDIMER: 0.98 10/12 SARS-COV-2 Variant Sequencing result: pending 10/12 ABG i-pH 7.47, i-PCo2 38, i-PO2 61, i-HCO3 27.3 10/13 FIBRINOGEN: 480 10/13 DDIMER: 0.83 10/13 ESR: 44 10/14 FIBRINOGEN: 406 10/14 DDIMER: 0.59 10/14 EST: 25 10/14 ABG: I-pH 7.44, i-PCo2 41, i-PO2 66, i-HCO3 27.8 10/15 FIBRINOGEN: 296 10/15 DDIMER: 0.60 10/15 ESR: 27 10/16 FIBRINOGEN: 300 10/16 DDIMER: 0.72 10/16 ESR: 18 10/17 FIBRINOGEN: 253 10/17 DDIMER: 0.92 10/17 ESR: 18 10/18 F8BR8H9GEH: 240 10/18 DDIMER: 0.93 10/18 ESR: 19 10/19 FIBRINOGEN: 242 10/19 DDIMER: 0.90 10/19 ESR: 13 10/21 FIBRINOGEN: 220 10/21 DDIMER: 0.67 10/21 ESR: 6 08/21 FIBRINOGEN: 197 08/21 DDIMER: 0.83 08/21 ESR: 4
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: PO2 decreased, Pneumoperitoneum, Procalcitonin increased, Prothrombin time prolonged, Pulmonary mass
Clinical narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/04, Pfizer, dose #2 10/02 Pt cc: dyspnea, cough, myalgias, fatigue, cough, exposure: unknown 10/12 pt admit to medicine cc shortness of breath : dx: ACUTE HYPOXIC RESPIRATORY FAILURE DUE TO COVID-19 PENUMONIA LOS: 10 days 10/21 u/s abdomen impression: 1. New bilateral obstruction or pneumoperitoneum. 10/12 CXR impression: 1. New bilateral airspace opacities could relate to pneumonia, including viral. 10/12 CTA PE impression: 1. Technically suboptimal study. No pulmonary embolus in the large central pulmonary arteries. Limited evaluation of the segmental and subsegmental pulmonary arteries. 2. Nonspecific groundglass densities in the lungs probably represent covid 19 pneumonia. Pleas correlate clinically and follow-up as appropriate. 3. Right Pulmonary nodules measuring up to 1.9 cm as above are again noted. Further evaluation and follow-up will be helpful as clinically appropriate. 4. Mild splenomegaly. 5. Nonobstructing left renal calculus. 10/12 TROPONIN I: <0.016 10/12 PT/INR: 16.7/1.49 10/12 FERRITIN: 1035.7 10/12 CRP: 11.387 10/12 PROCALCITONIN: ,0.05 10/12 BNP: 12.0 10/12 COVID swab, result: detected 10/12 DDIMER: 0.98 10/12 SARS-COV-2 Variant Sequencing result: pending 10/12 ABG i-pH 7.47, i-PCo2 38, i-PO2 61, i-HCO3 27.3 10/13 FIBRINOGEN: 480 10/13 DDIMER: 0.83 10/13 ESR: 44 10/14 FIBRINOGEN: 406 10/14 DDIMER: 0.59 10/14 EST: 25 10/14 ABG: I-pH 7.44, i-PCo2 41, i-PO2 66, i-HCO3 27.8 10/15 FIBRINOGEN: 296 10/15 DDIMER: 0.60 10/15 ESR: 27 10/16 FIBRINOGEN: 300 10/16 DDIMER: 0.72 10/16 ESR: 18 10/17 FIBRINOGEN: 253 10/17 DDIMER: 0.92 10/17 ESR: 18 10/18 F8BR8H9GEH: 240 10/18 DDIMER: 0.93 10/18 ESR: 19 10/19 FIBRINOGEN: 242 10/19 DDIMER: 0.90 10/19 ESR: 13 10/21 FIBRINOGEN: 220 10/21 DDIMER: 0.67 10/21 ESR: 6 08/21 FIBRINOGEN: 197 08/21 DDIMER: 0.83 08/21 ESR: 4
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate increased, SARS-CoV-2 test positive, Serum ferritin increased, Splenomegaly, Troponin I normal
Clinical narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/04, Pfizer, dose #2 10/02 Pt cc: dyspnea, cough, myalgias, fatigue, cough, exposure: unknown 10/12 pt admit to medicine cc shortness of breath : dx: ACUTE HYPOXIC RESPIRATORY FAILURE DUE TO COVID-19 PENUMONIA LOS: 10 days 10/21 u/s abdomen impression: 1. New bilateral obstruction or pneumoperitoneum. 10/12 CXR impression: 1. New bilateral airspace opacities could relate to pneumonia, including viral. 10/12 CTA PE impression: 1. Technically suboptimal study. No pulmonary embolus in the large central pulmonary arteries. Limited evaluation of the segmental and subsegmental pulmonary arteries. 2. Nonspecific groundglass densities in the lungs probably represent covid 19 pneumonia. Pleas correlate clinically and follow-up as appropriate. 3. Right Pulmonary nodules measuring up to 1.9 cm as above are again noted. Further evaluation and follow-up will be helpful as clinically appropriate. 4. Mild splenomegaly. 5. Nonobstructing left renal calculus. 10/12 TROPONIN I: <0.016 10/12 PT/INR: 16.7/1.49 10/12 FERRITIN: 1035.7 10/12 CRP: 11.387 10/12 PROCALCITONIN: ,0.05 10/12 BNP: 12.0 10/12 COVID swab, result: detected 10/12 DDIMER: 0.98 10/12 SARS-COV-2 Variant Sequencing result: pending 10/12 ABG i-pH 7.47, i-PCo2 38, i-PO2 61, i-HCO3 27.3 10/13 FIBRINOGEN: 480 10/13 DDIMER: 0.83 10/13 ESR: 44 10/14 FIBRINOGEN: 406 10/14 DDIMER: 0.59 10/14 EST: 25 10/14 ABG: I-pH 7.44, i-PCo2 41, i-PO2 66, i-HCO3 27.8 10/15 FIBRINOGEN: 296 10/15 DDIMER: 0.60 10/15 ESR: 27 10/16 FIBRINOGEN: 300 10/16 DDIMER: 0.72 10/16 ESR: 18 10/17 FIBRINOGEN: 253 10/17 DDIMER: 0.92 10/17 ESR: 18 10/18 F8BR8H9GEH: 240 10/18 DDIMER: 0.93 10/18 ESR: 19 10/19 FIBRINOGEN: 242 10/19 DDIMER: 0.90 10/19 ESR: 13 10/21 FIBRINOGEN: 220 10/21 DDIMER: 0.67 10/21 ESR: 6 08/21 FIBRINOGEN: 197 08/21 DDIMER: 0.83 08/21 ESR: 4
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Ultrasound abdomen abnormal
Clinical narrative: COVID infection following COVID vaccine series 02/10, Pfizer, dose #1 03/04, Pfizer, dose #2 10/02 Pt cc: dyspnea, cough, myalgias, fatigue, cough, exposure: unknown 10/12 pt admit to medicine cc shortness of breath : dx: ACUTE HYPOXIC RESPIRATORY FAILURE DUE TO COVID-19 PENUMONIA LOS: 10 days 10/21 u/s abdomen impression: 1. New bilateral obstruction or pneumoperitoneum. 10/12 CXR impression: 1. New bilateral airspace opacities could relate to pneumonia, including viral. 10/12 CTA PE impression: 1. Technically suboptimal study. No pulmonary embolus in the large central pulmonary arteries. Limited evaluation of the segmental and subsegmental pulmonary arteries. 2. Nonspecific groundglass densities in the lungs probably represent covid 19 pneumonia. Pleas correlate clinically and follow-up as appropriate. 3. Right Pulmonary nodules measuring up to 1.9 cm as above are again noted. Further evaluation and follow-up will be helpful as clinically appropriate. 4. Mild splenomegaly. 5. Nonobstructing left renal calculus. 10/12 TROPONIN I: <0.016 10/12 PT/INR: 16.7/1.49 10/12 FERRITIN: 1035.7 10/12 CRP: 11.387 10/12 PROCALCITONIN: ,0.05 10/12 BNP: 12.0 10/12 COVID swab, result: detected 10/12 DDIMER: 0.98 10/12 SARS-COV-2 Variant Sequencing result: pending 10/12 ABG i-pH 7.47, i-PCo2 38, i-PO2 61, i-HCO3 27.3 10/13 FIBRINOGEN: 480 10/13 DDIMER: 0.83 10/13 ESR: 44 10/14 FIBRINOGEN: 406 10/14 DDIMER: 0.59 10/14 EST: 25 10/14 ABG: I-pH 7.44, i-PCo2 41, i-PO2 66, i-HCO3 27.8 10/15 FIBRINOGEN: 296 10/15 DDIMER: 0.60 10/15 ESR: 27 10/16 FIBRINOGEN: 300 10/16 DDIMER: 0.72 10/16 ESR: 18 10/17 FIBRINOGEN: 253 10/17 DDIMER: 0.92 10/17 ESR: 18 10/18 F8BR8H9GEH: 240 10/18 DDIMER: 0.93 10/18 ESR: 19 10/19 FIBRINOGEN: 242 10/19 DDIMER: 0.90 10/19 ESR: 13 10/21 FIBRINOGEN: 220 10/21 DDIMER: 0.67 10/21 ESR: 6 08/21 FIBRINOGEN: 197 08/21 DDIMER: 0.83 08/21 ESR: 4
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/25, Pfizer, dose #1 02/16, Pfizer, dose #2 10/05 COVID swab, result: detected 10/02 pt cc: cough, diarrhea, fever, loss of taste or smell, rhinorrhea exposure: unknown 10/02 SARS-COV-2 Variant Sequencing result: pending
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Blood fibrinogen increased, Blood lactic acid, COVID-19, Cardiomegaly, Chest X-ray abnormal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/03, Pfizer, dose #1 04/23, Pfizer, dose #2 11/09 Pfizer, dose #3 10/12 pt cc: exposure: wife 10/12 COVID swab, result: detected 10/08 CT ABD & PELVIS impression: 1. Small fluid in the right paracolic gutter and dependent pelvis, nonspecific. Mild wall thickening or a distal ileal loop, correlate for any distal ileitis. 2. Appendix not clearly identified. 10/08 TROPONIN I: <0.016 10/08 CXR impression: No acute cardiopulmonary disease. 10/08 COVID swan, result: NOT detected 10/12 CXR Impression. New faint bilateral airspace opacities, particularly in the lung bases. Depending on clinical presentation, this could relate to Covid pneumonia versus mild pulmonary edema in the setting of cardiomegaly. 10/12 LACTIC ACID: 0.96 10/13 FIBRINOGEN: 555 10/13 DDIMER: 1.77 10/13 PROCALCITONIN: 0.13 10/13 ESR: 45 10/13 SARS COV2 IgG: 1.88 10/13 COVID swab, result: NOT detected 10/14 FIBRINOGEN: 515 10/14 DDIMER: 2.01 10/14 ESR: 32 10/15 FIBRINOGEN: 515 10/15 DDIMER: 1.85 10/15 ESR: 41 10/16 clinically resolved 10/25 COVID swab, result: detected
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram abdomen abnormal, Exposure to SARS-CoV-2, Fibrin D dimer increased, Lung opacity, Pelvic fluid collection
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/03, Pfizer, dose #1 04/23, Pfizer, dose #2 11/09 Pfizer, dose #3 10/12 pt cc: exposure: wife 10/12 COVID swab, result: detected 10/08 CT ABD & PELVIS impression: 1. Small fluid in the right paracolic gutter and dependent pelvis, nonspecific. Mild wall thickening or a distal ileal loop, correlate for any distal ileitis. 2. Appendix not clearly identified. 10/08 TROPONIN I: <0.016 10/08 CXR impression: No acute cardiopulmonary disease. 10/08 COVID swan, result: NOT detected 10/12 CXR Impression. New faint bilateral airspace opacities, particularly in the lung bases. Depending on clinical presentation, this could relate to Covid pneumonia versus mild pulmonary edema in the setting of cardiomegaly. 10/12 LACTIC ACID: 0.96 10/13 FIBRINOGEN: 555 10/13 DDIMER: 1.77 10/13 PROCALCITONIN: 0.13 10/13 ESR: 45 10/13 SARS COV2 IgG: 1.88 10/13 COVID swab, result: NOT detected 10/14 FIBRINOGEN: 515 10/14 DDIMER: 2.01 10/14 ESR: 32 10/15 FIBRINOGEN: 515 10/15 DDIMER: 1.85 10/15 ESR: 41 10/16 clinically resolved 10/25 COVID swab, result: detected
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Procalcitonin, Red blood cell sedimentation rate increased, SARS-CoV-2 antibody test, SARS-CoV-2 test negative, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/03, Pfizer, dose #1 04/23, Pfizer, dose #2 11/09 Pfizer, dose #3 10/12 pt cc: exposure: wife 10/12 COVID swab, result: detected 10/08 CT ABD & PELVIS impression: 1. Small fluid in the right paracolic gutter and dependent pelvis, nonspecific. Mild wall thickening or a distal ileal loop, correlate for any distal ileitis. 2. Appendix not clearly identified. 10/08 TROPONIN I: <0.016 10/08 CXR impression: No acute cardiopulmonary disease. 10/08 COVID swan, result: NOT detected 10/12 CXR Impression. New faint bilateral airspace opacities, particularly in the lung bases. Depending on clinical presentation, this could relate to Covid pneumonia versus mild pulmonary edema in the setting of cardiomegaly. 10/12 LACTIC ACID: 0.96 10/13 FIBRINOGEN: 555 10/13 DDIMER: 1.77 10/13 PROCALCITONIN: 0.13 10/13 ESR: 45 10/13 SARS COV2 IgG: 1.88 10/13 COVID swab, result: NOT detected 10/14 FIBRINOGEN: 515 10/14 DDIMER: 2.01 10/14 ESR: 32 10/15 FIBRINOGEN: 515 10/15 DDIMER: 1.85 10/15 ESR: 41 10/16 clinically resolved 10/25 COVID swab, result: detected
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Troponin I normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 04/03, Pfizer, dose #1 04/23, Pfizer, dose #2 11/09 Pfizer, dose #3 10/12 pt cc: exposure: wife 10/12 COVID swab, result: detected 10/08 CT ABD & PELVIS impression: 1. Small fluid in the right paracolic gutter and dependent pelvis, nonspecific. Mild wall thickening or a distal ileal loop, correlate for any distal ileitis. 2. Appendix not clearly identified. 10/08 TROPONIN I: <0.016 10/08 CXR impression: No acute cardiopulmonary disease. 10/08 COVID swan, result: NOT detected 10/12 CXR Impression. New faint bilateral airspace opacities, particularly in the lung bases. Depending on clinical presentation, this could relate to Covid pneumonia versus mild pulmonary edema in the setting of cardiomegaly. 10/12 LACTIC ACID: 0.96 10/13 FIBRINOGEN: 555 10/13 DDIMER: 1.77 10/13 PROCALCITONIN: 0.13 10/13 ESR: 45 10/13 SARS COV2 IgG: 1.88 10/13 COVID swab, result: NOT detected 10/14 FIBRINOGEN: 515 10/14 DDIMER: 2.01 10/14 ESR: 32 10/15 FIBRINOGEN: 515 10/15 DDIMER: 1.85 10/15 ESR: 41 10/16 clinically resolved 10/25 COVID swab, result: detected
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test negative, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 07/28 pt cc: cough, myalgias, fatigue; exposure: unknown 08/03 COVID swab, result: detected 08/06 clinically resolved 08/11 pt c/o body aches, loss of taste and smell but able to eat, feels he is improving 08/16 minimal cough, taste returned 08/25 pt reports close exposure to COVID positive person; COVID swab, result: not detected
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cough, Diarrhoea, Exposure to SARS-CoV-2, Headache
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 02/02, Pfizer, dose #1 02/23, Pfizer, dose #2 07/28 pt cc: cough, diarrhea, headache, rhinorrhea exposure: +COVID room mate & went to an event with grand-daughter 08/03 COVID swab, result: detected 08/04 pt report symptoms improving 08/06 pt cc: none clinically resolved
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 02/02, Pfizer, dose #1 02/23, Pfizer, dose #2 07/28 pt cc: cough, diarrhea, headache, rhinorrhea exposure: +COVID room mate & went to an event with grand-daughter 08/03 COVID swab, result: detected 08/04 pt report symptoms improving 08/06 pt cc: none clinically resolved
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chills, Cough, Diarrhoea, Exposure to SARS-CoV-2
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 03/05, Janssen, dose #1 08/03 COVID swab, result: detected 08/03 pt cc: chills, cough, diarrhea; exposure: unknown 08/10 PT cc: headache, sinus congestion,sinus pressure, rhinorrhea, myalgias 08/10 z-pack ordered
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Paranasal sinus discomfort, Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 03/05, Janssen, dose #1 08/03 COVID swab, result: detected 08/03 pt cc: chills, cough, diarrhea; exposure: unknown 08/10 PT cc: headache, sinus congestion,sinus pressure, rhinorrhea, myalgias 08/10 z-pack ordered
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Sinus congestion
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 03/05, Janssen, dose #1 08/03 COVID swab, result: detected 08/03 pt cc: chills, cough, diarrhea; exposure: unknown 08/10 PT cc: headache, sinus congestion,sinus pressure, rhinorrhea, myalgias 08/10 z-pack ordered
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chills, Cough, Dyspnoea, Fatigue
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 03/19, Pfizer, dose #1 04/09, Pfizer, dose #2 09/29 pt cc: cough, chills, fatigue, fever, headache, myalgias, thinorrhea, dyspnea, sre throat exposure: unknown 10/08 COVID swab, result: detected 10/08 SARS-COV-2 Variant Sequencing result: pending
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Myalgia, Oropharyngeal pain, Pyrexia, Rhinorrhoea
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 03/19, Pfizer, dose #1 04/09, Pfizer, dose #2 09/29 pt cc: cough, chills, fatigue, fever, headache, myalgias, thinorrhea, dyspnea, sre throat exposure: unknown 10/08 COVID swab, result: detected 10/08 SARS-COV-2 Variant Sequencing result: pending
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 03/19, Pfizer, dose #1 04/09, Pfizer, dose #2 09/29 pt cc: cough, chills, fatigue, fever, headache, myalgias, thinorrhea, dyspnea, sre throat exposure: unknown 10/08 COVID swab, result: detected 10/08 SARS-COV-2 Variant Sequencing result: pending
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Cold sweat, Dizziness, Hyperhidrosis, Injection site pain, Oesophageal spasm
Clinical narrative: Injection administed at 11:52 am, pt has reported diaphoresis,  lightheadedness, at 11:58 with sig pain at the injection site and some blotching redness. No bronchospasms, no laryngospasms, no sob, no chest pain, no chest  tightness. Pt profusely wet and clammy and lightheaded. In clinic rapid response called by RN. Vital signs done q5 min ( see rapid response outpatient scanned record). Pt then progressed to having itching and esophageal spasms. POD called.  Pt administered 25mg IM benadryl per POD instruction with worsened lightheadedness. 911 was called and transported pt to nearest hospital at 12:40
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash macular, Throat irritation
Clinical narrative: Injection administed at 11:52 am, pt has reported diaphoresis,  lightheadedness, at 11:58 with sig pain at the injection site and some blotching redness. No bronchospasms, no laryngospasms, no sob, no chest pain, no chest  tightness. Pt profusely wet and clammy and lightheaded. In clinic rapid response called by RN. Vital signs done q5 min ( see rapid response outpatient scanned record). Pt then progressed to having itching and esophageal spasms. POD called.  Pt administered 25mg IM benadryl per POD instruction with worsened lightheadedness. 911 was called and transported pt to nearest hospital at 12:40
Age: 44.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, COVID-19, Cough, Dyspnoea
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/05 COVID vaccine, Pfizer, dose #1 03/26 COVID vaccine, Pfizer,dose #2 07/29 pt cc: cough, fatigue, fever, loss of taste or smell, myalgias, rhinorrhea, dyspnea, sore throat 08/02 COVID swab, result: detected 08/10 clinically resolved
Age: 44.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Inappropriate schedule of product administration, Myalgia, Oropharyngeal pain, Pyrexia
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/05 COVID vaccine, Pfizer, dose #1 03/26 COVID vaccine, Pfizer,dose #2 07/29 pt cc: cough, fatigue, fever, loss of taste or smell, myalgias, rhinorrhea, dyspnea, sore throat 08/02 COVID swab, result: detected 08/10 clinically resolved
Age: 44.0
Sex: M
Vaccine: COVID19
Symptoms: Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 03/05 COVID vaccine, Pfizer, dose #1 03/26 COVID vaccine, Pfizer,dose #2 07/29 pt cc: cough, fatigue, fever, loss of taste or smell, myalgias, rhinorrhea, dyspnea, sore throat 08/02 COVID swab, result: detected 08/10 clinically resolved
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Antinuclear antibody negative, Arthralgia, Asthenia, C-reactive protein normal
Clinical narrative: Within three hours of receiving the vaccine, the injection site was erythemetous, swollen, and warm to touch. I began having shaking chills, HA, general myalgias and arthralgias, and abdominal cramping. This continued daily with worsening of symptoms to the point that I was unable to eat. On 11/4/2021, I developed severe vertigo and vomiting along with all the other symptoms and sought care at a local ED. I was given fluids, meclizine, and zofran and discharged home. The vertigo improved, but the other symptoms continued including a severe HA for which I was reseen in the ED on 11/6/2021. Treatment included fluids, pain medication, and anti-emetics. I was once again discharged home. I continued to have profound weakness, nausea, anorexia and was barely able to ambulate.   November 11,2021- I awakened with a significant visual defect in my left eye-multiple shadows in the medial inferior visual field. I was subsequently evaluated by an optometrist where retinal photographs reveal optic nerve swelling. I was immediately referred to a retinal specialist who diagnosed me with optic neuritis- probably vaccine related. I was placed on prednisone 20 mgs daily and valcyclovir 1000 mgs BID.  November 24,2021- recheck with retinal specialist- minimal change in optic neuritis OS-continued on prednisone and valcyclovir at same dosages.  My generalized weakness is gradually improving. I lost nearly 10 lbs during this entire illness, but my appetite has improved. The optic neurutus is presently the major issue. I am an emergency physician and unfortunately have been unable to work since November secondary to these issues. I am regularly being followed by my retinal specialist and internist.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Chest X-ray normal, Chills, Computerised tomogram head normal, Decreased appetite, Electrocardiogram normal
Clinical narrative: Within three hours of receiving the vaccine, the injection site was erythemetous, swollen, and warm to touch. I began having shaking chills, HA, general myalgias and arthralgias, and abdominal cramping. This continued daily with worsening of symptoms to the point that I was unable to eat. On 11/4/2021, I developed severe vertigo and vomiting along with all the other symptoms and sought care at a local ED. I was given fluids, meclizine, and zofran and discharged home. The vertigo improved, but the other symptoms continued including a severe HA for which I was reseen in the ED on 11/6/2021. Treatment included fluids, pain medication, and anti-emetics. I was once again discharged home. I continued to have profound weakness, nausea, anorexia and was barely able to ambulate.   November 11,2021- I awakened with a significant visual defect in my left eye-multiple shadows in the medial inferior visual field. I was subsequently evaluated by an optometrist where retinal photographs reveal optic nerve swelling. I was immediately referred to a retinal specialist who diagnosed me with optic neuritis- probably vaccine related. I was placed on prednisone 20 mgs daily and valcyclovir 1000 mgs BID.  November 24,2021- recheck with retinal specialist- minimal change in optic neuritis OS-continued on prednisone and valcyclovir at same dosages.  My generalized weakness is gradually improving. I lost nearly 10 lbs during this entire illness, but my appetite has improved. The optic neurutus is presently the major issue. I am an emergency physician and unfortunately have been unable to work since November secondary to these issues. I am regularly being followed by my retinal specialist and internist.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Feeding disorder, Full blood count normal, Gait disturbance, Headache, Herpes simplex test negative
Clinical narrative: Within three hours of receiving the vaccine, the injection site was erythemetous, swollen, and warm to touch. I began having shaking chills, HA, general myalgias and arthralgias, and abdominal cramping. This continued daily with worsening of symptoms to the point that I was unable to eat. On 11/4/2021, I developed severe vertigo and vomiting along with all the other symptoms and sought care at a local ED. I was given fluids, meclizine, and zofran and discharged home. The vertigo improved, but the other symptoms continued including a severe HA for which I was reseen in the ED on 11/6/2021. Treatment included fluids, pain medication, and anti-emetics. I was once again discharged home. I continued to have profound weakness, nausea, anorexia and was barely able to ambulate.   November 11,2021- I awakened with a significant visual defect in my left eye-multiple shadows in the medial inferior visual field. I was subsequently evaluated by an optometrist where retinal photographs reveal optic nerve swelling. I was immediately referred to a retinal specialist who diagnosed me with optic neuritis- probably vaccine related. I was placed on prednisone 20 mgs daily and valcyclovir 1000 mgs BID.  November 24,2021- recheck with retinal specialist- minimal change in optic neuritis OS-continued on prednisone and valcyclovir at same dosages.  My generalized weakness is gradually improving. I lost nearly 10 lbs during this entire illness, but my appetite has improved. The optic neurutus is presently the major issue. I am an emergency physician and unfortunately have been unable to work since November secondary to these issues. I am regularly being followed by my retinal specialist and internist.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Impaired work ability, Injection site erythema, Injection site swelling, Injection site warmth, Metabolic function test normal
Clinical narrative: Within three hours of receiving the vaccine, the injection site was erythemetous, swollen, and warm to touch. I began having shaking chills, HA, general myalgias and arthralgias, and abdominal cramping. This continued daily with worsening of symptoms to the point that I was unable to eat. On 11/4/2021, I developed severe vertigo and vomiting along with all the other symptoms and sought care at a local ED. I was given fluids, meclizine, and zofran and discharged home. The vertigo improved, but the other symptoms continued including a severe HA for which I was reseen in the ED on 11/6/2021. Treatment included fluids, pain medication, and anti-emetics. I was once again discharged home. I continued to have profound weakness, nausea, anorexia and was barely able to ambulate.   November 11,2021- I awakened with a significant visual defect in my left eye-multiple shadows in the medial inferior visual field. I was subsequently evaluated by an optometrist where retinal photographs reveal optic nerve swelling. I was immediately referred to a retinal specialist who diagnosed me with optic neuritis- probably vaccine related. I was placed on prednisone 20 mgs daily and valcyclovir 1000 mgs BID.  November 24,2021- recheck with retinal specialist- minimal change in optic neuritis OS-continued on prednisone and valcyclovir at same dosages.  My generalized weakness is gradually improving. I lost nearly 10 lbs during this entire illness, but my appetite has improved. The optic neurutus is presently the major issue. I am an emergency physician and unfortunately have been unable to work since November secondary to these issues. I am regularly being followed by my retinal specialist and internist.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Optic neuritis, Papilloedema, Red blood cell sedimentation rate normal
Clinical narrative: Within three hours of receiving the vaccine, the injection site was erythemetous, swollen, and warm to touch. I began having shaking chills, HA, general myalgias and arthralgias, and abdominal cramping. This continued daily with worsening of symptoms to the point that I was unable to eat. On 11/4/2021, I developed severe vertigo and vomiting along with all the other symptoms and sought care at a local ED. I was given fluids, meclizine, and zofran and discharged home. The vertigo improved, but the other symptoms continued including a severe HA for which I was reseen in the ED on 11/6/2021. Treatment included fluids, pain medication, and anti-emetics. I was once again discharged home. I continued to have profound weakness, nausea, anorexia and was barely able to ambulate.   November 11,2021- I awakened with a significant visual defect in my left eye-multiple shadows in the medial inferior visual field. I was subsequently evaluated by an optometrist where retinal photographs reveal optic nerve swelling. I was immediately referred to a retinal specialist who diagnosed me with optic neuritis- probably vaccine related. I was placed on prednisone 20 mgs daily and valcyclovir 1000 mgs BID.  November 24,2021- recheck with retinal specialist- minimal change in optic neuritis OS-continued on prednisone and valcyclovir at same dosages.  My generalized weakness is gradually improving. I lost nearly 10 lbs during this entire illness, but my appetite has improved. The optic neurutus is presently the major issue. I am an emergency physician and unfortunately have been unable to work since November secondary to these issues. I am regularly being followed by my retinal specialist and internist.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Retinogram abnormal, SARS-CoV-2 test negative, Tremor, Vertigo, Visual field defect
Clinical narrative: Within three hours of receiving the vaccine, the injection site was erythemetous, swollen, and warm to touch. I began having shaking chills, HA, general myalgias and arthralgias, and abdominal cramping. This continued daily with worsening of symptoms to the point that I was unable to eat. On 11/4/2021, I developed severe vertigo and vomiting along with all the other symptoms and sought care at a local ED. I was given fluids, meclizine, and zofran and discharged home. The vertigo improved, but the other symptoms continued including a severe HA for which I was reseen in the ED on 11/6/2021. Treatment included fluids, pain medication, and anti-emetics. I was once again discharged home. I continued to have profound weakness, nausea, anorexia and was barely able to ambulate.   November 11,2021- I awakened with a significant visual defect in my left eye-multiple shadows in the medial inferior visual field. I was subsequently evaluated by an optometrist where retinal photographs reveal optic nerve swelling. I was immediately referred to a retinal specialist who diagnosed me with optic neuritis- probably vaccine related. I was placed on prednisone 20 mgs daily and valcyclovir 1000 mgs BID.  November 24,2021- recheck with retinal specialist- minimal change in optic neuritis OS-continued on prednisone and valcyclovir at same dosages.  My generalized weakness is gradually improving. I lost nearly 10 lbs during this entire illness, but my appetite has improved. The optic neurutus is presently the major issue. I am an emergency physician and unfortunately have been unable to work since November secondary to these issues. I am regularly being followed by my retinal specialist and internist.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting, Weight decreased
Clinical narrative: Within three hours of receiving the vaccine, the injection site was erythemetous, swollen, and warm to touch. I began having shaking chills, HA, general myalgias and arthralgias, and abdominal cramping. This continued daily with worsening of symptoms to the point that I was unable to eat. On 11/4/2021, I developed severe vertigo and vomiting along with all the other symptoms and sought care at a local ED. I was given fluids, meclizine, and zofran and discharged home. The vertigo improved, but the other symptoms continued including a severe HA for which I was reseen in the ED on 11/6/2021. Treatment included fluids, pain medication, and anti-emetics. I was once again discharged home. I continued to have profound weakness, nausea, anorexia and was barely able to ambulate.   November 11,2021- I awakened with a significant visual defect in my left eye-multiple shadows in the medial inferior visual field. I was subsequently evaluated by an optometrist where retinal photographs reveal optic nerve swelling. I was immediately referred to a retinal specialist who diagnosed me with optic neuritis- probably vaccine related. I was placed on prednisone 20 mgs daily and valcyclovir 1000 mgs BID.  November 24,2021- recheck with retinal specialist- minimal change in optic neuritis OS-continued on prednisone and valcyclovir at same dosages.  My generalized weakness is gradually improving. I lost nearly 10 lbs during this entire illness, but my appetite has improved. The optic neurutus is presently the major issue. I am an emergency physician and unfortunately have been unable to work since November secondary to these issues. I am regularly being followed by my retinal specialist and internist.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: Pt given IM Benadryl 50mg and 911 called, but pt refused to go to ER. Vet was monitored for 30 minutes post Covid-19 injection due to hx of reactions to other immunizations and oral medications. Pt received ride home from husband.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19 pneumonia, SARS-CoV-2 test positive
Clinical narrative: Narrative:  69yr patient received J&J COVID vaccine 4/2021. Admitted to medical facility (9/1 to 9/10) secondary to COVID + PNA and acute hypoxic respiratory failure. Pertinent history: COPD, ESRD on HD, obesity, HTN, HFpEF, and DM2. Patient received dexamethasone 6mg daily along with ceftriaxone and azithryomycin.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Atelectasis, Blood fibrinogen normal, COVID-19, Chest X-ray normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 10/10 pt admit to medicine cc: fall dx: Diziness, COVID + LOS: 3 days 10/10 pt cc: exposure: unknown 10/10 COVID swab, result: detected 10/10 CXR Impression: Clear lungs without acute findings 10/11 CTA PE Impression: 1. No large pulmonary embolism identified. Small area of subtle low attenuation area within a subsegmental pulmonary artery to the left lower lobe, favored to reflect artifact from patient respiratory motion given associated findings. Small pulmonary embolism is difficult to entirely exclude in the setting of high clinical suspicion. 2. Two new small ground glass opacities in the left upper lobe and a new focal ground glass opacity in the left lower lobe, which may reflect an infectious/inflammatory process. Focal opacity in the inferior left upper lobe reflects atelectasis. Attention on follow-up imaging to confirm resolution. 10/11 FIBRINOGEN: 264 10/11 DDIMER: 0.99 10/11 ESR: 300 10/12 DDIMMER: 1.01 10/12 ESR: 5 10/13 FIBRINOGEN: 281 10/13 DDIMER: 0.98 10/13 ESR: 11
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Fall, Fibrin D dimer, Lung opacity, Pulmonary embolism
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 10/10 pt admit to medicine cc: fall dx: Diziness, COVID + LOS: 3 days 10/10 pt cc: exposure: unknown 10/10 COVID swab, result: detected 10/10 CXR Impression: Clear lungs without acute findings 10/11 CTA PE Impression: 1. No large pulmonary embolism identified. Small area of subtle low attenuation area within a subsegmental pulmonary artery to the left lower lobe, favored to reflect artifact from patient respiratory motion given associated findings. Small pulmonary embolism is difficult to entirely exclude in the setting of high clinical suspicion. 2. Two new small ground glass opacities in the left upper lobe and a new focal ground glass opacity in the left lower lobe, which may reflect an infectious/inflammatory process. Focal opacity in the inferior left upper lobe reflects atelectasis. Attention on follow-up imaging to confirm resolution. 10/11 FIBRINOGEN: 264 10/11 DDIMER: 0.99 10/11 ESR: 300 10/12 DDIMMER: 1.01 10/12 ESR: 5 10/13 FIBRINOGEN: 281 10/13 DDIMER: 0.98 10/13 ESR: 11
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate increased, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 10/10 pt admit to medicine cc: fall dx: Diziness, COVID + LOS: 3 days 10/10 pt cc: exposure: unknown 10/10 COVID swab, result: detected 10/10 CXR Impression: Clear lungs without acute findings 10/11 CTA PE Impression: 1. No large pulmonary embolism identified. Small area of subtle low attenuation area within a subsegmental pulmonary artery to the left lower lobe, favored to reflect artifact from patient respiratory motion given associated findings. Small pulmonary embolism is difficult to entirely exclude in the setting of high clinical suspicion. 2. Two new small ground glass opacities in the left upper lobe and a new focal ground glass opacity in the left lower lobe, which may reflect an infectious/inflammatory process. Focal opacity in the inferior left upper lobe reflects atelectasis. Attention on follow-up imaging to confirm resolution. 10/11 FIBRINOGEN: 264 10/11 DDIMER: 0.99 10/11 ESR: 300 10/12 DDIMMER: 1.01 10/12 ESR: 5 10/13 FIBRINOGEN: 281 10/13 DDIMER: 0.98 10/13 ESR: 11
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary normal, Arteriosclerosis, Blood bicarbonate increased, Blood fibrinogen normal, Blood gases
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 05/10 Janssen, dose #1 10/08 pt admit to medicine cc: fall dx: COVID-19 penumonia.LOS: 10 days 10/08 CXR impression: Hazy density in the left mid to lower lung zone with more subtle patchy density in the left mid lung, which could represent pneumonia. 10/08 CTA PE impression: 1. No CT evidence of a large central pulmonary embolism. 2. Diffuse glass opacities throughout the lung parenchyma.  Finding may be consistent with the patient's positive COVID status. 3. Emphysematous lung parenchyma. 4. Atherosclerosis. 10/08 BNP: 68.7 10/08 TROPONIN I: 0.037 10/08 COVID swab, result: detected 10/08 SARS-COV-2 Variant Sequencing result: pending 10/08 FIBRINOGEN: 384 10/08 DDIMER: 1.21 10/08 CRP: 15.527 10/08 ABG: i-pH 7.50, i-PCo2 37.3, i-PO2 46, i-HCO3 28.9 10/08 FIBRINOGEN: 281 10/08 DDIMER: 1.25 10/08 ESR: 19 10/08 FERRITIN: 753.8 10/09 PROCALCITONIN <0.05 10/09 LACTIC ACID: 0.91 10/09 SARS-COV-2 Variant Sequencing result: 2500.0 10/09 troponin i: 0.040 10/09 SARS-CCOV-2-IgG: 0.03 10/10 FIBRINOGEN: 378 10/10 DDIMER: 1.20 10/10 ESR: 33 10/11 FIBRINOGEN: 288 10/11 DDIMER: 0.97 10/11 ESR: 19 10/12 COVID swab, result: detected 10/12 pt cc: exposure: unknown 10/12 FIBRINOGEN: 308 10/12 DDIMER: 1.03 1012 ESR: 29 10/13 FIBRINOGEN: 242 10/13 DDIMER: 1.29 10/13 ESR: 31 10/14 FIBRINOGEN: 245 10/15 DDIMER: 1.50 10/15 ESR: 23 10/15 FIBRINOGEN: 208 10/15 DDIMER: 1.76 10/15 ESR: 21 10/16 FIBRINOGEN: 247 10/16 DDIMER: 1.71 10/16 ESR: 30 10/17 FIBRINOGEN: 255 10/17 DDIMER: 1.40 10/17 ESR: 15
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pH increased, Brain natriuretic peptide normal, C-reactive protein increased, COVID-19, COVID-19 pneumonia
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 05/10 Janssen, dose #1 10/08 pt admit to medicine cc: fall dx: COVID-19 penumonia.LOS: 10 days 10/08 CXR impression: Hazy density in the left mid to lower lung zone with more subtle patchy density in the left mid lung, which could represent pneumonia. 10/08 CTA PE impression: 1. No CT evidence of a large central pulmonary embolism. 2. Diffuse glass opacities throughout the lung parenchyma.  Finding may be consistent with the patient's positive COVID status. 3. Emphysematous lung parenchyma. 4. Atherosclerosis. 10/08 BNP: 68.7 10/08 TROPONIN I: 0.037 10/08 COVID swab, result: detected 10/08 SARS-COV-2 Variant Sequencing result: pending 10/08 FIBRINOGEN: 384 10/08 DDIMER: 1.21 10/08 CRP: 15.527 10/08 ABG: i-pH 7.50, i-PCo2 37.3, i-PO2 46, i-HCO3 28.9 10/08 FIBRINOGEN: 281 10/08 DDIMER: 1.25 10/08 ESR: 19 10/08 FERRITIN: 753.8 10/09 PROCALCITONIN <0.05 10/09 LACTIC ACID: 0.91 10/09 SARS-COV-2 Variant Sequencing result: 2500.0 10/09 troponin i: 0.040 10/09 SARS-CCOV-2-IgG: 0.03 10/10 FIBRINOGEN: 378 10/10 DDIMER: 1.20 10/10 ESR: 33 10/11 FIBRINOGEN: 288 10/11 DDIMER: 0.97 10/11 ESR: 19 10/12 COVID swab, result: detected 10/12 pt cc: exposure: unknown 10/12 FIBRINOGEN: 308 10/12 DDIMER: 1.03 1012 ESR: 29 10/13 FIBRINOGEN: 242 10/13 DDIMER: 1.29 10/13 ESR: 31 10/14 FIBRINOGEN: 245 10/15 DDIMER: 1.50 10/15 ESR: 23 10/15 FIBRINOGEN: 208 10/15 DDIMER: 1.76 10/15 ESR: 21 10/16 FIBRINOGEN: 247 10/16 DDIMER: 1.71 10/16 ESR: 30 10/17 FIBRINOGEN: 255 10/17 DDIMER: 1.40 10/17 ESR: 15
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Carbon dioxide normal, Chest X-ray abnormal, Computerised tomogram thorax abnormal, Emphysema, Fall
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 05/10 Janssen, dose #1 10/08 pt admit to medicine cc: fall dx: COVID-19 penumonia.LOS: 10 days 10/08 CXR impression: Hazy density in the left mid to lower lung zone with more subtle patchy density in the left mid lung, which could represent pneumonia. 10/08 CTA PE impression: 1. No CT evidence of a large central pulmonary embolism. 2. Diffuse glass opacities throughout the lung parenchyma.  Finding may be consistent with the patient's positive COVID status. 3. Emphysematous lung parenchyma. 4. Atherosclerosis. 10/08 BNP: 68.7 10/08 TROPONIN I: 0.037 10/08 COVID swab, result: detected 10/08 SARS-COV-2 Variant Sequencing result: pending 10/08 FIBRINOGEN: 384 10/08 DDIMER: 1.21 10/08 CRP: 15.527 10/08 ABG: i-pH 7.50, i-PCo2 37.3, i-PO2 46, i-HCO3 28.9 10/08 FIBRINOGEN: 281 10/08 DDIMER: 1.25 10/08 ESR: 19 10/08 FERRITIN: 753.8 10/09 PROCALCITONIN <0.05 10/09 LACTIC ACID: 0.91 10/09 SARS-COV-2 Variant Sequencing result: 2500.0 10/09 troponin i: 0.040 10/09 SARS-CCOV-2-IgG: 0.03 10/10 FIBRINOGEN: 378 10/10 DDIMER: 1.20 10/10 ESR: 33 10/11 FIBRINOGEN: 288 10/11 DDIMER: 0.97 10/11 ESR: 19 10/12 COVID swab, result: detected 10/12 pt cc: exposure: unknown 10/12 FIBRINOGEN: 308 10/12 DDIMER: 1.03 1012 ESR: 29 10/13 FIBRINOGEN: 242 10/13 DDIMER: 1.29 10/13 ESR: 31 10/14 FIBRINOGEN: 245 10/15 DDIMER: 1.50 10/15 ESR: 23 10/15 FIBRINOGEN: 208 10/15 DDIMER: 1.76 10/15 ESR: 21 10/16 FIBRINOGEN: 247 10/16 DDIMER: 1.71 10/16 ESR: 30 10/17 FIBRINOGEN: 255 10/17 DDIMER: 1.40 10/17 ESR: 15